Physician profile
Bimal Padaliya
NPI 1467571299
$32,632.91
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,851 · 2020: $1,109 · 2021: $3,169 · 2022: $14K · 2023: $1,791 · 2024: $3,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,680 · Honoraria: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,680.44 |
| Honoraria | $2,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19,422.15 | 2019-2024 | Cardiomems, Amplatzer Talisman |
| Boston Scientific Corporation | $3,043.22 | 2019-2024 | Watchman Access System, Avvigo Guidance System |
| Medtronic, INC. | $2,949.45 | 2021-2023 | Onyx Frontier |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $2,724.45 | 2022-2024 | Lifevest |
| Medtronic Vascular, INC. | $1,832.72 | 2019-2020 | |
| Amgen INC. | $417.19 | 2020-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $370.19 | 2019-2024 | Farxiga, Andexxa |
| Novartis Pharmaceuticals Corporation | $283.94 | 2023-2024 | |
| Heartflow, INC. | $255.17 | 2022-2023 | Ffrct |
| Impulse Dynamics (USA) INC. | $214.62 | 2023-2024 | Optimizer, Optimizer |
| Abiomed | $162.16 | 2022-2023 | Impella |
| Zoll Circulation INC | $120.93 | 2024 | Therox Ds2 Console, Downstream Cartridge, Catheter |
| Alnylam Pharmaceuticals INC. | $101.77 | 2023-2024 | Amvuttra |
| Pfizer INC. | $100.02 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.31 | 2023-2024 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $81.47 | 2023 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $73.12 | 2023-2024 | Camzyos |
| Zoll Respicardia, INC. | $67.82 | 2023-2024 | Remede System |
| Janssen Pharmaceuticals, INC | $54.64 | 2023-2024 | Xarelto |
| Atricure, INC. | $42.57 | 2023 | |
| Philips North America LLC | $36.37 | 2023 | |
| Teleflex LLC | $33.41 | 2024 | Quikclot |
| Edwards Lifesciences Corporation | $29.51 | 2022 | |
| Itamar Medical INC | $29.49 | 2023-2024 | Watchpatone |
| Actelion Pharmaceuticals US, INC. | $28.03 | 2023 | Opsumit, Uptravi |
| Cvrx, INC. | $24.50 | 2024 | Barostim Neo System |
| Chiesi USA, INC. | $18.78 | 2020 | |
| Astellas Pharma US INC | $15.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bimal Padaliya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.